title: Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.
abstract: OBJECTIVE
  To investigate the effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.
  
  
  METHODS
  Randomized, placebo-controlled, double-masked, 2-drug crossover study with 10 patients with cornea guttata and 10 healthy controls, who had mean endothelial cell counts of 988 and 2377 cells/mm(2), respectively. Study medications were 2% dorzolamide and placebo drops applied 3 times a day for 4 weeks. Central corneal thickness measurements using ACMaster (Carl Zeiss Meditec AG, Jena, Germany) and Goldmann applanation tonometry were performed at baseline, 1 day, 1 week, and 4 weeks.
  
  
  RESULTS
  The mean increases in central corneal thickness after 4 weeks in eyes with cornea guttata treated with dorzolamide and placebo were 26.3 microm (95% confidence interval, 8.8 to 43.7) and 3.3 microm (95% confidence interval, -0.5 to 7.1), respectively. No statistically significant changes were measured in the healthy control group. Dorzolamide caused a significant decrease in intraocular pressure (P < .01) while placebo did not cause significant changes (P = .50).
  
  
  CONCLUSIONS
  Application of dorzolamide for 4 weeks resulted in a statistically significant increase in central corneal thickness in patients with compromised corneal endothelium. These results indicate that patients with corneal endothelial problems receiving dorzolamide therapy should be monitored.
authors.affiliation: Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
authors.forename: Matthias G
authors.initials: MG
authors.lastname: Wirtitsch
authors.forename: Oliver
authors.initials: O
authors.lastname: Findl
authors.forename: Harald
authors.initials: H
authors.lastname: Heinzl
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Drexler
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001837:Body Weights and Measures; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D002452:Cell Count; D003315:Cornea / Q000187:drug effects* / Q000473:pathology; D003316:Corneal Diseases / Q000150:complications*; D015715:Corneal Edema / Q000139:chemically induced / Q000175:diagnosis; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004728:Endothelium, Corneal / Q000473:pathology; D005260:Female; D006801:Humans; D007368:Interferometry; D007429:Intraocular Pressure / Q000187:drug effects; D008027:Light; D008297:Male; D008875:Middle Aged; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects*; D014065:Tonometry, Ocular
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide